Mode
Text Size
Log in / Sign up

Systematic review and meta-analysis on left atrial strain parameters predicting AF recurrence.

Systematic review and meta-analysis on left atrial strain parameters predicting AF recurrence.
Photo by Navy Medicine / Unsplash
Key Takeaway
Consider left atrial strain parameters as associative predictors for AF recurrence, noting limited predictive power for some measures.

This is a systematic review and meta-analysis of 25 studies covering 3,649 patients, synthesizing evidence on left atrial strain parameters (PALS, LASr, LAScd, LASct) as predictors of atrial fibrillation (AF) recurrence. The authors found that higher PALS (categorical) was linked to a significantly lower risk of AF relapse (RR = 0.08, 95% CI: 0.04–0.16), and higher LASr (categorical) was also linked to a lower risk (RR = 0.91, 95% CI: 0.86–0.96). For continuous variables, a 1-unit increase in PALS was associated with a lower risk of AF recurrence (RR = 0.88, 95% CI: 0.85–0.91), and a 1-unit increase in LASr was associated with a lower risk (RR = 0.93, 95% CI: 0.88–0.99). The pooled AUC for PALS was 0.75 and for LASr was 0.78 for predictive performance. A unit elevation in LASct (measured after treatment) was linked to a reduced risk of AF relapse (RR = 0.75, 95% CI: 0.63–0.91). The authors note that the predictive power of other parameters (LASct and LAScd measured before treatment, LASr measured after treatment) was limited or unclear (all P > 0.05). The analysis used a random-effects model to pool risk ratios. Practice relevance is limited to associative findings, and causation should not be inferred.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BackgroundClinical evidence, in recent years, has increased regarding the application of left atrial strain parameters for the prediction of atrial fibrillation (AF) recurrence. This study endeavors to assess the predictive power of these parameters for AF recurrence.MethodsWe systematically searched Cochrane Library, Embase, PubMed, and Web of Science from inception to October 20, 2025, for cohort studies investigating the association between AF recurrence and various left atrial strain parameters, including peak atrial longitudinal strain (PALS, P-wave-triggered), left atrial reservoir strain (LASr, R-wave-triggered), left atrial conduit strain (LAScd), and left atrial contraction strain (LASct). A random-effects model was used to pool risk ratios (RRs) and predictive performance metrics. Sensitivity analysis, publication bias assessment, and subgroup analysis were performed.ResultsTotally 25 studies covering 3,649 patients were included. The meta-analysis indicated that PALS and LASr measured before treatment were effective predictors for AF recurrence. Analyzed as categorical variables, both a higher PALS (RR = 0.08, 95% CI: 0.04–0.16) and a higher LASr (RR = 0.91, 95% CI: 0.86–0.96) were linked to a significantly lower risk of AF relapse. Treated as continuous variables, a 1-unit increase in PALS (RR = 0.88, 95% CI: 0.85–0.91) or LASr (RR = 0.93, 95% CI: 0.88–0.99) was associated with a pronounced lower risk of AF recurrence. The pooled AUC values for PALS and LASr were 0.75 and 0.78, respectively. The predictive power of other parameters was limited or unclear: LASct and LAScd measured before treatment, as well as LASr measured after treatment (either as a categorical variable or a continuous variable), failed to show significant predictive power (all P > 0.05). Only for LASct measured after treatment as a continuous variable, each unit elevation in LASct was linked to a reduced risk of AF relapse (RR = 0.75, 95% CI: 0.63–0.91).ConclusionThis study suggests that lower PALS and LASr values are associated with a higher risk of AF recurrence. In addition, PALS and LASr shows relatively favorable predictive performance for AF recurrence.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251182805, identifier: CRD420251182805.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.